Jpmorgan Chase & CO Beam Therapeutics Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 639,238 shares of BEAM stock, worth $16.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
639,238
Previous 690,065 7.37%
Holding current value
$16.6 Million
Previous $16.2 Million 3.14%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Dec 26, 2024
SELL
$22.57 - $33.14 $1.15 Million - $1.68 Million
-50,827 Reduced 7.37%
639,238 $15.7 Million
Q3 2024

Nov 08, 2024
SELL
$22.57 - $33.14 $1.15 Million - $1.68 Million
-50,827 Reduced 7.37%
639,238 $15.7 Million
Q2 2024

Dec 26, 2024
BUY
$21.22 - $32.66 $1.08 Million - $1.66 Million
50,827 Added 7.95%
690,065 $16.2 Million
Q2 2024

Aug 12, 2024
BUY
$21.22 - $32.66 $4.77 Million - $7.33 Million
224,579 Added 48.25%
690,065 $16.2 Million
Q1 2024

Dec 26, 2024
SELL
$23.46 - $45.07 $4.08 Million - $7.83 Million
-173,752 Reduced 27.18%
465,486 $15.4 Million
Q1 2024

May 10, 2024
SELL
$23.46 - $45.07 $1.36 Million - $2.61 Million
-57,947 Reduced 11.07%
465,486 $15.4 Million
Q4 2023

Dec 26, 2024
SELL
$17.69 - $30.76 $2.05 Million - $3.56 Million
-115,805 Reduced 18.12%
523,433 $14.2 Million
Q4 2023

Feb 12, 2024
SELL
$17.69 - $30.76 $2.46 Million - $4.28 Million
-139,122 Reduced 21.0%
523,433 $14.2 Million
Q3 2023

Nov 14, 2023
SELL
$23.01 - $32.46 $1.04 Million - $1.46 Million
-45,125 Reduced 6.38%
662,555 $15.9 Million
Q2 2023

Aug 11, 2023
SELL
$29.32 - $35.99 $423,820 - $520,235
-14,455 Reduced 2.0%
707,680 $22.6 Million
Q1 2023

May 18, 2023
BUY
$30.15 - $48.79 $2.47 Million - $3.99 Million
81,796 Added 12.77%
722,135 $22.1 Million
Q1 2023

May 11, 2023
SELL
$30.15 - $48.79 $3.05 Million - $4.93 Million
-101,076 Reduced 13.63%
640,339 $19.6 Million
Q4 2022

Feb 13, 2023
SELL
$36.73 - $51.6 $504,706 - $709,035
-13,741 Reduced 1.82%
741,415 $29 Million
Q3 2022

Nov 14, 2022
BUY
$39.79 - $70.31 $648,417 - $1.15 Million
16,296 Added 2.21%
755,156 $36 Million
Q2 2022

Aug 11, 2022
SELL
$29.86 - $62.36 $113,736 - $237,529
-3,809 Reduced 0.51%
738,860 $28.6 Million
Q1 2022

May 11, 2022
BUY
$53.73 - $82.16 $514,464 - $786,682
9,575 Added 1.31%
742,669 $42.6 Million
Q4 2021

Feb 10, 2022
BUY
$68.02 - $99.06 $7.25 Million - $10.6 Million
106,582 Added 17.01%
733,094 $58.4 Million
Q3 2021

Nov 12, 2021
BUY
$84.37 - $133.6 $52.9 Million - $83.7 Million
626,512 New
626,512 $54.5 Million

Others Institutions Holding BEAM

# of Institutions
233
Shares Held
75.1M
Call Options Held
438K
Put Options Held
232K
View Full List

About Beam Therapeutics Inc.

BEAM Quotes by TradingView
  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.83B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email